Tagged as: Pricing

Oversight Committee Launches “Sweeping Drug Price Investigation” Regarding Biologics

On Jan. 14, Rep. Elijah E. Cummings, the Chairman of the Committee on Oversight and Reform, issued a press release that his office had sent letters to 12 drug companies seeking “detailed information and documents about the companies’ pricing practices,”  including material regarding price increases, investments in research and development,…

Read More

WSJ Reports on Biosimilar Pricing in the U.S.

Today, the Wall Street Journal published an article by Jonathan D. Rockoff that takes an in-depth look at the actual and expected pricing of biosimilars in the U.S.  For those with WSJ subscriptions, it is well worth a read: http://www.wsj.com/articles/knockoffs-of-biotech-drugs-bring-paltry-savings-1462458209.

Read More